checkpoint inhibitor

June 4, 2019

Cancer Vaccine Shows Potential against iNHL in Early Results

News

A new cancer vaccine still in clinical testing showed potential for driving disease remission in patients with advanced indolent non-Hodgkin’s lymphoma (iNHL) and may help restore efficacy of immunotherapies, including ... Read more

February 18, 2019

Opdivo Effective for Relapsed/Refractory Classical Hodgkin’s Lymphoma, Meta-analysis Suggests

News

Immune checkpoint inhibitor Opdivo (nivolumab) appears to be more effective at treating patients with relapsed or refractory classical Hodgkin’s lymphoma than other therapies, a meta-analysis suggests. The study, “Efficacy of ... Read more

February 8, 2019February 5, 2019

The Joy of a New Oncologist

Columns, Things That Give Me Hope - a Column by Bob McEachern

I seem to have bad luck with oncologists. I was diagnosed with follicular lymphoma a little over 11 years ago. But in the last five years, I have had five ... Read more

June 4, 2018

Alexo Begins Testing ALX148 Combinations in Phase 1 Trial of NHL, Solid Tumors

News

Alexo Therapeutics has started treating patients in the combination part of its Phase 1 trial, which will test multiple combinations of ALX148 with targeted antibody therapies — including Keytruda (pembrolizumab), Herceptin ... Read more

June 30, 2017June 30, 2017

85% of Hodgkin Lymphoma Patients Respond to Adcetris-Opdivo Combo, Trial Shows

News

A combination of Adcetris (brentuximab vedotin) and Opdivo (nivolumab) led to Hodgkin lymphoma diminishing in 85 percent of patients in a Phase 1/2 trial (NCT02572167), researchers reported. Among them, 63 ... Read more

February 16, 2017

Lymphoma Patients Respond to Pembrolizumab After Other Therapies Fail, Small Study Indicates

News

Patients with NK-cell or T-cell lymphomas whose previous treatments failed showed remarkably good responses to the immunotherapy Keytruda (pembrolizumab) in a small trial. The study, “PD1 blockade with pembrolizumab is ... Read more